Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials

Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials

Demonstrating a slowing in the rate of cognitive decline is a common outcome measure in clinical trials in Alzheimer’s disease (AD). Selection of cognitive endpoints typically includes modeling candidate outcome measures in the many, richly phenotyped observational cohort studies available. An impor...

Full description

Bibliographic Details
Main Authors: Andrew J. Aschenbrenner, Jason Hassenstab, Guoqiao Wang, Yan Li, Chengjie Xiong, Eric McDade, David B. Clifford, Stephen Salloway, Martin Farlow, Roy Yaari, Eden Y. J. Cheng, Karen C. Holdridge, Catherine J. Mummery, Colin L. Masters, Ging-Yuek Hsiung, Ghulam Surti, Gregory S. Day, Sandra Weintraub, Lawrence S. Honig, James E. Galvin, John M. Ringman, William S. Brooks, Nick C. Fox, Peter J. Snyder, Kazushi Suzuki, Hiroyuki Shimada, Susanne Gräber, Randall J. Bateman
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Aging Neuroscience
Subjects:
practice effects
Alzheimer’s disease
clinical trials
learning
assessment frequency
alternative forms
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2022.883131/full

Internet

https://www.frontiersin.org/articles/10.3389/fnagi.2022.883131/full

Similar Items